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Abstract
Background: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal-dominant vascular disorder,
characterized by recurrent epistaxis, mucocutaneous telangiectases, and arteriovenous malformations (AVMs) in
various visceral organs. Endoglin (ENG) and activin receptor-like kinase 1 (ACVRL1; ALK1), receptors for transforming
growth factor-b (TGF-b) superfamily, have been identified as the principal HHT-causing genes.
Methods: Three unrelated Korean HHT patients and their asymptomatic as well as symptomatic family members
were genetically diagnosed by sequencing whole exons and their flanking regions of ENG and ACVRL1.
Functionality of an aberrant translation start codon, which is created by a substitution mutation at the 5’-
untranslated region (UTR) of ENG found in a HHT family, was tested by transient in vitro transfection assay. Decay
of the mutant transcripts was also assessed by allele-specific expression analysis.
Results: Two ENG and one ACVRL1 mutations were identified: a known ENG mutation (c.360+1G > A; p.
Gly74_Tyr120del); a novel ENG mutation (c.1-127C > T); and a novel ACVRL1 mutation (c.252_253insC; p.
Val85fsX168). We further validated that the 5’-UTR ENG mutation prevents translation of ENG from the biological
translation initiation site of the mutant allele, and leads to degradation of the mutant transcripts.
Conclusions: This is the first experimental demonstration that a 5’-UTR mutation can prevent translation of ENG
among HHT patients, and further supports the previous notion that haploinsufficiency is the primary mechanism of
HHT1. Our data also underscore the importance of including exons encoding 5’ UTR for HHT mutation screening.
Background
Hereditary hemorrhagic telangiectasia (HHT) is a rare
genetic vascular disorder, inherited in an autosomal-
dominant trait. With a regional variance, HHT affects
about 1 in 5,000 to 8,000 people worldwide [1-3]. Major
clinical diagnosis criteria include family history, recur-
rent epistaxis, mucocutaneous telangiectases, and arter-
iovenous malformations (AVMs) in internal organs such
as the lung, brain, and liver [4,5]. Epistaxis is usually the
earliest clinical symptom of HHT that appears at teens,
while cutaneous and gastrointestinal telangiectases man-
ifest at adulthood ages. However, both of these
symptoms progressively worsen with age, and manifest
in more than 90% of HHT patients in their 60’s [1].
Five clinically indistinguishable types of HHT are
defined by associated genetic loci. HHT1 (MIM
#187300) and HHT2 (MIM #600376) that account for
more than 80% of HHT are caused by heterozygous
mutations in endoglin (ENG) [6-8] and activin receptor-
like kinase 1 (ACVRL1; ALK1) [9-11] genes, respectively
[12,13]. To date, 397 ENG and 332 ACVRL1 mutations
and polymorphisms have been reported [14]. Two addi-
tional genetic loci on chromosomes 5 and 7 were identi-
fied for HHT3 (MIM #601011) and HHT4 (MIM
#610655), respectively [15,16]. A group of juvenile poly-
posis patients harboring mutations in the SMAD4 gene
d i s p l a yac o m b i n e ds y n d r o m ew i t hH H T( J P - H H T )
(MIM #175050) [17]. Based on the fact that ENG,
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tor of transforming growth factor-b (TGF-b)f a m i l ys i g -
nals, it has been postulated that impaired signaling of
TGF-b family member(s) would be an important patho-
logical mechanism of HHT. Recent biochemical studies
have suggested that BMP9 is the plausible physiological
ligand of ALK1 [18-20].
Since clinical diagnosis of HHT has limitations due to
the late onset, incomplete penetrance, and variability of
disease manifestations, genetic diagnosis is valuable not
only to confirm the clinical diagnosis but also to identify
asymptomatic carriers among a HHT family. Early
screening of asymptomatic patients for cerebral and pul-
monary AVMs that are found in about 40% of HHT
patients can prevent them from potential serious health
risks such as stroke and brain abscess [1].
Despite dozens of HHT case reports for Korean HHT
families, only one genetic study identifying genetic
mutations has been reported [21]. Here, we report
genetic analyses of three unrelated Korean HHT families
diagnosed by clinical criteria. We found one known and
one novel mutations in ENG, and one novel mutation in
ACVRL1. With molecular analysis, we demonstrate that
the novel ENG mutation found in the 5’-untranslated
region (UTR) initiates aberrant translation that prevents
translation of ENG from the biological translation initia-
tion site of the mutant allele, and leads to nonsense-
mediated mRNA decay.
Methods
Human subjects
Experimental procedures performed were reviewed and
approved by the Ethics Committee, an institutional
review board, at Lee Gil Ya Cancer and Diabetes Insti-
tute, Gachon University, Incheon, Korea. Patients were
diagnosed with HHT when they possessed at least three
of the four Curaçao established criteria: 1) an affected
first degree family member; 2) recurrent nosebleeds; 3)
multiple telangiectases along the mucocutaneous sur-
face; and 4) AVMs in major organs [22]. HHT genetic
analysis was then conducted after obtaining informed
consent from patients and their family members. Clini-
cal features of patients reported by clinicians are sum-
marized in Table 1. Only obviously detected symptoms
are listed. Since systematic screening was not employed,
visceral AVMs and skin telangiectasia might have been
missed from some patients.
Genomic DNA isolation
Blood samples were collected in vacuum blood collec-
tion tubes containing EDTA. Genomic DNA was iso-
lated from 200-μl blood samples using the Exgene Blood
SV mini kit (GeneAll, South Korea) according to the
manufacturer’s protocol.
PCR amplification and sequence analysis of ENG and
ACVRL1 exons
All exons of ENG and ACVRL1 genes, including non-
coding regions and flanking intronic sequences, were
amplified by genomic polymerase chain reaction (PCR)
using PrimeSTAR HS DNA Polymerase (TAKARA,
Japan) and the appropriate primer sets (Additional file
1; Table S1). PCR products were separated in a 1-2%
agarose gel and purified using QIAquick Gel Extraction
Kit (QIAGEN, Germany) or Expin PCR SV kit (GeneAll,
Korea). These purified PCR products were then directly
Table 1 Clinical features and mutations of three HHT families
Family Patient Gender/Age Clinical features Mutations
I I-1 M/46 Epistaxis ENG c.360+1G > A, p.Gly74_Tyr120del
I-2 M/43 Epistaxis, PAVM, Epilepsy,
Cerebral abscess
ENG c.360+1G > A, p.Gly74_Tyr120del
I-3 F/41 Epistaxis, PAVM ENG c.360+1G > A, p.Gly74_Tyr120del
I-4 F/14 Epistaxis, PAVM ENG c.360+1G > A, p.Gly74_Tyr120del
I-5 F/12 Epistaxis ENG c.360+1G > A, p.Gly74_Tyr120del
II II-1 F/82 Epistaxis,
Skin telangiectasia
ENG c.1-127 C > T, new upstream
translation start codon (TSC)
II-2 M/65 Epistaxis, CAVM ENG c.1-127 C > T, new upstream TSC
II-3 M/53 Epistaxis ENG c.1-127 C > T, new upstream TSC
II-4 F/50 Epistaxis ENG c.1-127 C > T, new upstream TSC
II-5 M/13 Epistaxis, CAVM, dead n/d
II-6 M/18 Epistaxis, PAVM, Seizure,
Embolic cerebral infarction
ENG c.1-127 C > T, new upstream TSC
III III-1 M/55 Epistaxis ACVRL1 c.252_253insC, p.Val85fsX168
III-2 M/50 Epistaxis ACVRL1 c.252_253insC, p.Val85fsX168
III-3 F/40 Epistaxis ACVRL1 c.252_253insC, p.Val85fsX168
n/d: not determined
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sequences used in this study are [GenBank:
NM_000118.2] (cDNA) and [GenBank:NC_009551.1]
(genomic DNA) for ENG, and [GenBank:NM_000020.2]
(cDNA) and [GenBank:NC_009545.1] (genomic DNA)
for ACVRL1.
Plasmid construction and transient in vitro transfection
ENG 5’-UTRs (position -413 to -1) of wild-type (WT)
and mutant (M) alleles from genomic DNA of HHT
patients in Family 2 (Figures 1) were amplified via
PCR and subcloned into T&A Cloning Vectors (Real
Biotech Corporation, Taiwan), yielding pTA-ENG-WT
Figure 1 Pedigree and genetic analysis of three HHT families.( A) Pedigree of families with genetic mutations and/or symptoms of HHT.
Pedigree symbols: filled symbol, affected individual; open symbol, unaffected individual; divided symbol, affected individual by hearsay; gray
symbol, no phenotypical and genetic data available. A slashed symbol indicates that the individual is deceased. Genetic analysis was performed
on all individuals represented by filled and open symbols. Genetic mutations and HHT-associated symptoms of numbered patients are
summarized in Table 1. (B) Genetic studies of three representative family members with HHT. Family 1, ENG c.360+1G > A (p.Gly74_Tyr120del);
Family 2, ENG c.1-127 C > T (aberrant translation); Family 3, ACVRL1 c.252_253insC (p.Val85fsX168). The amino acid translation is shown above
each codon. The amino acid sequence in Family 2 is the predicted sequence translated from the aberrant translation start codon. Arrows
indicate mutation sites. SD, splicing donor sequence.
Kim et al. BMC Medical Genetics 2011, 12:130
http://www.biomedcentral.com/1471-2350/12/130
Page 3 of 10and pTA-ENG-M. The ENG c.1-127 C > T mutation
created a putative translation start codon in the 5’-
UTR of pTA-ENG-M. WT and mutant 5’-UTRs were
amplified with hENF-5UTR-F1 (gctagcctctacccggttgg-
caggcggcct) and hENF-5UTR-R1 (ccatgGtgtc-
cacgtgggggcctgtgcg) from WT and mutant ENG alleles,
respectively. For cloning purpose, an NheI site (under-
lined) was introduced at the 5’-end of the forward pri-
mer and the ‘G’ nucleotide at position -2 in the 5’-
UTR was replaced with ‘C’, which produced an NcoI
site (underlined) at the 5’-end of the reverse primer.
The luciferase gene in pGL4.14 [luc2/hygro] (Promega,
USA) was subcloned into the NcoI and XbaI sites in
pTA-ENG-WT and pTA-ENG-M plasmids, generating
pTA-ENG-WT-luc and pTA-ENG-M-luc, respectively.
The eGFP gene in pEGFP-N1 (Clontech, USA) was
replaced with the ENG 5’-UTR-luciferase fragments of
pTA-ENG-WT-luc and pTA-ENG-M-luc. The substi-
tuted ‘C’ nucleotide at position -2 to produce the NcoI
site reverted to the original ‘G’ nucleotide by site
directed mutagenesis (COSMO GENETECH, Korea),
generating pENG-luc(WT) and pENG-luc(M), respec-
tively (Figure 2A). A plasmid with an artificial 5’-UTR,
which was produced by insertion of a ‘C’ nucleotide
between -41 and -40 of the mutant 5’-UTR in pENG-
luc(M), was generated and designated pENG-luc(M+1)
(Figure 2A). The inserted ‘C’ nucleotide between -41
and -40 resulted in a frameshift and produced a luci-
ferase fusion protein translated from the aberrant
translation start codon (Figure 2A).
The plasmids were transfected into HepG2, a human
hepatocellular liver carcinoma cell line, with Magneta-
min (LPS Solution, South Korea) according to manufac-
turer’s instructions. Cells were harvested 48 h after
transfection. The luciferase activity was measured with
the Enhanced Luciferase Assay Kit (BD Biosciences,
USA) and normalized with b-galactosidase activity using
b-galactosidase Enzyme Assay System (Promega, USA).
Allele-specific expression analysis
Total RNAs were isolated from blood using RNAiso Plus
(TAKARA, Japan). Reverse transcription was performed
with Prime RT-Premix (2×) (Genet Bio, Korea) using
ENG-specific R3 primer (5’-cctggagagtcagctccagctgtg-3’).
The PCR primers, F2 (5’-ctgctgtcactgccatccattgga-3’)a n d
R2 (5’-agacctggctagtggtatatgtca-3’), were used for amplifi-
cation of the ENG cDNA. Genomic DNA was amplified
using F1 (5’-ccatccttcggacagcaactccag-3’)a n dR 1( 5 ’-
ccaccctgggtccctggacaccta-3’). Amplified PCR products
were digested with BtsCI, which recognizes GGATG (i.e.
mutant specific) sequence, and analyzed on an 8% polya-
crylamide gel to determine whether the PCR product
possessed ENG c.1-127 C > T mutation. The PCR pro-
ducts were also subjected to direct sequencing.
Real-time RT-PCR
Total RNAs were isolated from blood samples of unaf-
fected and affected individuals using RNAiso Plus
(TAKARA, Japan) and first-strand cDNA was synthesized
Figure 2 Functionality of the aberrant translation start codon.( A)
Schematic representation of the pENG-luc constructs. Wild-type (WT)
ENG promoter produces ENG mRNA including the 413-nt-5’-UTR.
pENG-luc(WT) was designed to code for luciferase mRNA containing
the same ENG 5’-UTR under the control of the immediate early
promoter of CMV (CMV-IE). In pENG-luc(M), the ‘C’ at position -127 in
pENG-luc(WT) was replaced with ‘T’ (underlined), which generated the
aberrant translation start codon. The substitution was found in the
mutant allele of HHT patients in Family 2. The aberrant translation start
codon putatively produces a 72-amino acid-protein out of frame with
the luciferase coding sequence. In pENG-luc(M+1), a ‘C’ nucleotide
(bold) was inserted between -41 and -40 of pENG-luc(M), thus
producing an aberrant translation start codon that was in frame with
the luciferase coding sequence. Nucleotides are numbered with c.1
corresponding to the ‘A’ of the ATG translation start codon in the
reference sequence [GenBank:NM_000118.2]. (B) Bar graph illustrating
the results of luciferase assays. HepG2 cells were transfected with
pENG-luc plasmids [pENG-luc(WT), pENG-luc(M), or pENG-luc(M+1)] plus
the b-galactosidase plasmid. Luciferase activity was normalized to b-
galactosidase activity. The luciferase activity of pENG-luc(M) was
significantly reduced compared to that of pENG-luc(WT). The activity
was restored to levels even higher than WT levels in pENG-luc(M+1),
which produced an in-frame luciferase fusion protein (44 aa-luciferase).
Separate transfections were performed for each of three separate
experiments (n = 9). Data represent mean ± SD. *p <. 0 0 0 1 ,a s
determined by Student’s t test.
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with oligo(dT) primer. Real-time PCR was carried out
using SYBR Premix DimerEraser Kit (TAKARA, Japan)
and CFX384 Real-Time system (Bio-Rad, USA). A
human Cyclophilin primer set (Forward, 5’-tgccatcgc-
caaggagtag-3’; Reverse, 5’-tgcacagacggtcactcaaa-3’)w a s
used to normalize the amount of total cDNA in each
sample. Predesigned PCR primer for amplifying the Exon
3a n d4r e g i o no ft h eENG gene (PrimerBank ID
168693646b1) [23-25] was used to determine the amount
of ENG cDNA in each sample. Each sample was run in
triplicate. After 40 cycles of PCR reaction, the relative
amount of ENG transcripts was determined using the
ΔΔCt method.
Results
Clinical features and mutations
Clinical features and mutations of patients are summar-
ized in Table 1. Pedigree of HHT families is represented
in Figure 1A.
Family 1
The proband is a 43-year-old man (I-2), diagnosed as
HHT with recurrent epistaxis, pulmonary AVM
(PAVM) (Figure 3A), and family history of epistaxis
and/or PAVM. He had also suffered for epilepsy and
cerebral abscess (Figure 3B) when he was 26 and 40
years old, respectively. These brain symptoms were
most likely due to PAVMs that were recently treated
with coil embolization. His two daughters (I-4 and I-5),
brother (I-1), and sister (I-3), have experienced frequent
nosebleeds and/or PAVM. This trait can be traced to
great-grandmother of the proband.
Family 2
The proband is an 18-year-old man (II-6). He was diag-
nosed as HHT with recurrent epistaxis, PAVM, and
family history of recurrent epistaxis [26]. He had seizure
and embolic cerebral infarction [26]. These neurological
complications might be associated with PAVM. Stroke,
cerebral abscess, seizure, transient ischemic attacks, and
migraine headaches were observed in 9%, 8%, 37%, and
43% PAVM patients, respectively [27]. A history of epis-
taxis was found in his relatives on the mother’ss i d e
(patient II-1, II-2, II-3, II-4) [26]. His grandmother (II-1)
has telangiectasis lesions on the lips and skin, and his
uncle (II-2) had cerebral AVM (CAVM), and his cousin
(II-5) died of CAVM.
Family 3
The proband is a 55-year-old man (III-1) who was sus-
pected to be a HHT patient due to recurrent epistaxis
and familial history. His brother (III-2) and sister (III-3)
suffer from epistaxis. No history of visceral AVM was
reported in the family.
Figure 3 Clinical features of an HHT patient (I-2). PAVM (arrows) and cerebral abscess (arrow head) are detected by chest computed
tomography (CT) (A) and brain CT (B), respectively.
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PCR amplicons of whole exons and their flanking
regions of ENG and ACVRL1 from genomic DNA of
HHT patients and their family members (Figure 1,
Table 1) were directly sequenced.
Family 1
We identified a heterozygous mutation in the splicing
donor sequence in intron 3 of ENG (c.360+1G > A)
from the proband sample. This mutation was previously
reported that it causes an in-frame deletion of exon 3
(47 amino acids; p.Gly74_Tyr120del) and that the
mutant protein fails to localize at the plasma membrane
but stays in the cytosol [28]. Genetic analysis from
symptomatic and asymptomatic family members identi-
fied the same mutation from family members with epis-
taxis and/or PAVM. No mutation was found in two
children of the affected proband’s sister (I-3).
Family 2
No mutation was found in the coding region and spli-
cing junctions of either of ENG and ACVRL1 in the pro-
band (II-6), but a substitution mutation in the 5’-UTR of
ENG c.1-127 C > T. Interestingly, the same mutation
was found in his mother (II-4, obligate carrier) and only
in her symptomatic family members (II-1, -2, -3). The
suspected mutation (-128ACG-126 with -128ATG-126)
could generate a putative translation start codon in the
5’-UTR. If the putative translation start codon is func-
tional, the ENG mutant allele would prevent the transla-
tion initiation from the translation start codon of
normal ENG protein and produce an 84-amino acid-
protein out of frame with the ENG-coding sequence
instead. We confirmed with molecular analyses
(described below) that this is indeed the case.
Family 3
We identified a novel 1-base pair (bp) insertional muta-
tion in the ACVRL1 locus from the proband (III-1), and
the same mutation was found in his affected sibling (III-
2, -3). The ‘C’ nucleotide insertion in exon3
(c.252_253insC) would result in premature termination
of translation (p.Val85fsX168) and production of trun-
cated protein of size 167 amino acids instead of 503
amino acids full-length protein.
Functional tests of aberrant translation start codon found
in Family 2
To investigate the extent to which the putative transla-
tion start codon created by mutation in the 5’-UTR of
ENG identified in Family 2 inhibits normal ENG transla-
tion, we generated luciferase reporter constructs. These
reporter constructs contain 5’-UTR regions (-413 to -1)
of wild-type (WT) or of the mutant (M; c.1-127 C > T)
ENG gene including the biological translation initiation
sequence that was fused in frame with luciferase cDNA
(Figure 2A). If the putative translation start codon by
c.1-127 C > T mutation was functional and dominant
over the endogenous start codon, the translated product
f r o mt h ep u t a t i v es t a r tc o d o nw o u l db eo u to ff r a m e
with the luciferase coding sequence, and thus no lucifer-
ase activity would be detected. As shown in Figure 2B,
the luciferase activity from the cells transfected with
pENG-luc(M) was dramatically lower than that with
pENG-luc(WT), suggesting that the putative translation
initiation sequence functions as the dominant transla-
tion start codon and prevents translation of functional
luciferase. This notion was further supported by the
results from the assay using the pENG-luc(M+1) repor-
ter, in which single nucleotide was inserted between
positions -41 and -40 of the pENG-luc(M). This single
nucleotide insertion makes the translation from the
putative translation start codon of pENG-luc(M+1)
reporter in frame with the luciferase coding sequence.
The luciferase activity from the cells transfected with
the pENG-luc(M+1) reporter was even higher than that
with the pENG-luc(WT) reporter, indicating that the
putative translation start codon was able to produce a
functional luciferase fusion protein. These results
demonstrate that the aberrant translation start codon in
the mutant ENG allele of Family 2 is functional and
inhibits normal translation of the endogenous ENG
protein.
The aberrant translation start codon in the mutant
allele creates a new open reading frame (ORF), which is
252 bp in length and has a termination codon in exon2.
The mutant transcript could be a target of the non-
sense-mediated mRNA decay [29,30], a surveillance
mechanism, which degrades transcripts with nonsense
mutations for preventing the production of erroneous
proteins. To test this, we performed a restriction frag-
ment length polymorphism (RFLP) analysis and direct
sequencing of genomic DNA- and RT-PCR products
using templates isolated from blood samples of unaf-
fected and affected family members. The ENG c.1-127 C
> T mutation introduces the BtsCI restriction site
(GGATG) on the PCR product amplified from the
mutant allele. As anticipated, BtsCI digestion on PCR
products from genomic DNA templates demonstrated
the presence of PCR amplicon of the mutant allele only
from affected individuals (Figure 4A). On the other
hand, the BtsCI-sensitive PCR amplicon was barely
detectable from RT-PCR templates of affected indivi-
duals (Figure 4A), suggesting a much lower level of
transcripts from the mutant allele compared with those
from WT allele. Direct sequencing of RT-PCR products
also confirmed the diminished mutant transcripts.
Direct sequencing of PCR amplicons from genomic tem-
plate of an affected family member (patient II-4) showed
similar height of ‘C’ and ‘T’ peaks amplified from WT
and mutant alleles, respectively (Figure 4B). However,
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Page 6 of 10Figure 4 Allele-specific expression analyses of the ENG c.1-127 C > T mutant allele.( A) Restriction fragment length polymorphism analysis.
(Left panel) F1 and R1 primers were used for amplification of the ENG genomic DNA. BtsCI, which recognizes the mutant allele, digested of 313
bp PCR product from the mutant allele into 216 bp and 97 bp fragments (arrowheads). The mutant allele-specific BtsCI-digested PCR products
were detected in affected family member (Patient II-3) but not in an unaffected family member. (Right panel) F2 and R2 primers were used to
amplify ENG transcripts from ENG cDNA generated by reverse transcriptase using ENG-specific R3 primer. BtsCI digestion of RT-PCR product
amplified from mutant allele is supposed to yield 284 bp and 97 bp fragments if the mutant transcripts are stably present. Unlike genomic PCR
products, BtsCI-digested PCR fragments from RT-PCR products of affected individuals were barely detectable (arrowheads). (B) Direct sequencing
of the PCR products amplified from genomic DNA of a patient II-4 and cDNAs of an unaffected family member and three patients (II-2, II-3, II-4).
The ENG c.1-127 positions were indicated by arrows. (C) Real-time RT-PCR analysis of ENG transcripts. Total RNAs isolated from the blood of three
unaffected persons and three patients (II-2, II-3, II-4) were used for first-strand cDNA synthesis. Mean values of ENG ΔΔCt ratios and standard
deviations are shown as filled box and bar above each box, respectively. The relative amount of ENG transcripts in each sample was normalized
with the amount of Cyclophilin in the sample. * p < 0.01, compared with the unaffected samples, as determined by Student’s t test.
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cing of RT-PCR products of three patients (patient II-2,
-3, -4). To further confirm nonsense-mediated mRNA
decay of ENG transcripts from the mutant allele, we quan-
tified the amount of ENG mRNA using a real-time RT-
PCR on RNAs isolated from unaffected and affected indi-
viduals (Figure 4C). The levels of ENG transcripts in the
affected members (II-2, II-3, II-4) appear to be significantly
lower than those in unaffected controls. Taken together,
these results suggest that the substitution mutation (ENG
c.1-127 C > T) in the 5’-UTR of ENG creates an aberrant
translation start site which leads to frameshift and non-
sense-mediated mRNA decay of the mutant transcript.
Discussion
We identified two ENG and one ACVRL1 mutations in
genetic analyses of three unrelated Korean HHT
families. Here, the ENG c.1-127 C > T mutation in
Family 2 and the ACVRL1 c.252_253insC mutation in
Family 3 are reported for the first time (Figure 1).
Through in vitro luciferase reporter assay, we demon-
strated that the C > T substitution (c.1-127 C > T) in
the 5’-UTR of ENG is the disease-causing mutation in
Family 2 (Figure 1, 2). Mutations in the 5’-UTR are very
rare in HHT patients. Bossler et al. reported the c.1-10
C > T mutation in the ENG 5’-UTR of a patient with
H H T[ 3 1 ] ,w h i c hi st h eo n l yk n o w n5 ’-UTR mutation
among reported ACVRL1 and ENG mutations, except
large deletion mutations that include the 5’-UTRs [14].
Although the patient with the ENG c.1-10 C > T muta-
tion had recurrent epistaxis, PAVM, and a suggestive
family history, no experimental data testing the func-
tionality of the mutant allele was reported.
Generally, eukaryotic ribosomes bind to 5’-end cap of
mRNA and scan along the mRNA in the 5’ to 3’ direc-
tion until the first translation start codon is found, thus
initiating protein synthesis [32]. This ‘position effect’ is
evident in cases in which a mutation creates an ATG
codon upstream of the endogenous translation start
codon [32]. The new ATG initiates translation and sup-
presses translation from the endogenous ATG. The
optimal sequence surrounding the translation start
codon is 5’-gcc(a/g)ccATGg-3’ in mammals [32]. Within
the context, the purine (A or G) at position -3 is the
most important nucleotide. Additionally, the ‘G’ at posi-
tion +4 is also highly conserved, especially in the
absence of ‘A’ at position -3. According to mutagenesis
experiments, the sequence contexts generating the most
robust translation are 5’-annATGn-3’ or 5’-gnnATGg
[32]. When the context lacks both the purine at position
-3 and the ‘G’ at position +4, most ribosomes skip the
ATG and continue scanning the sequence downstream.
I nt h ec a s eo fas e q u e n c ei nw h i c ho n l yo n eo ft h e s e
nucleotides is conserved, initiation of translation from
the suboptimal ATG depends on several factors includ-
ing downstream secondary structure and the remaining
nucleotides surrounding the ATG codon [32]. The
e n d o g e n o u sa n dm u t a n tt r a n s l a t i o ns t a r tc o d o n si nt h e
mutant ENG allele are of the following sequence con-
texts: 5’-gacagcATGg-3’ (endogenous) and 5’-gcagg-
gATGc-3’ (mutant). The sequences surrounding the
endogenous translation start codon contains a purine
( A )a tp o s i t i o n- 3a n d‘G’ at position +4. On the other
hand, the mutant translation start context has a purine
( G )a tp o s i t i o n- 3 ,b u t‘C’ instead of ‘G’ at position +4.
Our data from the functional assays reported here
demonstrate that the suboptimal mutant translation
start context is functionally active and dominate over
the translation from the endogenous translation start
context (Figure 2). Furthermore, we present that the
mutation results in mRNA degradation (Figure 4),
which might be caused by nonsense-mediated mRNA
decay [29,30]. A critical determinant of nonsense-
mediated mRNA decay is the distance between the
translation start codon and premature termination
codon. Generally, premature termination codons located
at least 50-55 nt upstream of the last exon-exon junc-
tion leads to strong nonsense-mediated mRNA decay
responses. The ENG c.1-127 C > T mutation creates a
new open reading frame (ORF), which is 252 bp in
length. The distance between the termination codon of
the new ORF and the last exon-exon junction is more
than 1.5 kb, which satisfies the 50-55 nt boundary rule.
Conclusions
Three unrelated Korean HHT families were analyzed
clinically and genetically. We found HHT-causing ENG
or ACVRL1 mutations in these families. Consistent with
HHT clinical reports worldwide, the mutation carriers
exhibit diverse clinical symptoms even among family
members, and epistaxis is the most common symptom
among HHT1 and HHT2 patients. We presented experi-
mental demonstration for the first time in the HHT
f i e l dt h a ta5 ’-UTR mutation creates alternative transla-
tion initiation sequence, suppresses normal translation
of ENG from its endogenous translation start codon,
and leads to degradation of the mutant transcripts. In
addition to other known cases [4,33,34], this finding
provides further supporting evidence that haploinsuffi-
ciency is predominant mechanism of HHT1. Our data
also underscore the importance of including exons
encoding 5’ UTR for HHT mutation screening.
Additional material
Additional file 1: A title listing the PCR primers for ACVRL1 and
ENG genomic PCR. PCR primer sequences that were used for amplifying
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ENG genes.
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